Welcome to our dedicated page for Atea Pharmaceuticals news (Ticker: AVIR), a resource for investors and traders seeking the latest updates and insights on Atea Pharmaceuticals stock.
Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) is a clinical-stage biopharmaceutical company focused on oral antiviral therapeutics for serious viral diseases, and its news flow reflects this development-driven profile. Company announcements frequently center on progress in its hepatitis C virus (HCV) program, where Atea is advancing a fixed-dose combination regimen of bemnifosbuvir, a nucleotide analog HCV NS5B polymerase inhibitor, and ruzasvir, an NS5A inhibitor.
News items include updates on the global Phase 3 HCV program, such as enrollment milestones in the C-BEYOND and C-FORWARD trials, expectations for topline results, and details of trial design, endpoints and patient populations. Atea also reports new clinical and nonclinical data, including Phase 2 efficacy results, resistance analyses, pharmacokinetic findings and multiscale modeling that explore the regimen’s antiviral activity, barrier to resistance, relative bioavailability and dosing flexibility.
Investors and observers can also find press releases about Atea’s participation in major medical and investor conferences, including presentations at The Liver Meeting of the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver Congress, as well as appearances at healthcare investment conferences. These communications often highlight new data sets, key opinion leader events and discussions of the HCV commercial landscape.
In addition, Atea’s news coverage includes pipeline expansion updates, notably the development of nucleotide analog candidates AT-587 and AT-2490 for hepatitis E virus (HEV), along with background on the unmet medical need in HEV and the company’s preclinical findings. Financial results releases and business updates, furnished in connection with quarterly reports, provide further context on research and development spending, cash resources and strategic priorities. For those tracking AVIR, this news page offers a centralized view of clinical progress, scientific presentations, pipeline evolution and corporate developments.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference.
The company's management team will engage in a fireside chat on September 9, 2025, at 1:05 p.m. ET in New York. Investors can access the presentation through a live webcast on the company's investor relations website, with the recording remaining available for at least 90 days after the event.
Atea Pharmaceuticals (Nasdaq: AVIR) reported Q2 2025 financial results and provided updates on its HCV treatment program. The company's Phase 3 trials (C-BEYOND and C-FORWARD) are advancing for its bemnifosbuvir/ruzasvir combination therapy, with enrollment on track in both studies. The Phase 2 study showed promising results with a 98% sustained virologic response at 12 weeks post-treatment.
Financial highlights include cash position of $379.7 million as of June 30, 2025, compared to $454.7 million at end of 2024. The company reported a net loss of $37.2 million for Q2 2025. Atea has repurchased 4.6 million shares at an average price of $3.01 per share under its $25 million buyback program and is exploring strategic alternatives with Evercore.
The company presented four scientific posters at EASL 2025, demonstrating the potential best-in-class profile of its HCV regimen with advantages including short treatment duration, low drug-drug interaction risk, and no food effect requirements.
Atea Pharmaceuticals (Nasdaq: AVIR), a clinical-stage biopharmaceutical company focused on developing oral antiviral therapeutics, has scheduled its second quarter 2025 financial results and business update conference call for August 7, 2025, at 4:30 p.m. ET.
The company will host both a live conference call and audio webcast, with the webcast available under the "Events and Presentations" section of Atea's investor relations website. Participants can join via phone by dialing 1-877-300-8521 (U.S.) or 1-412-317-6026 (International) using conference ID 10201618.
Atea Pharmaceuticals (Nasdaq: AVIR) has announced the dosing of its first patient in the global Phase 3 C-FORWARD trial outside North America for its HCV treatment program. The trial evaluates the combination of bemnifosbuvir and ruzasvir against sofosbuvir and velpatasvir for hepatitis C virus treatment.
The treatment regimen is administered once-daily for 8 weeks in patients without cirrhosis or 12 weeks in patients with compensated cirrhosis. This marks the second Phase 3 trial in Atea's global program, following C-BEYOND which began enrolling patients in the US and Canada in April 2025.
The company aims to develop a best-in-class HCV regimen with potential advantages including shorter treatment duration, low risk for drug-drug interactions, and no food effect requirements. HCV remains a significant health burden, affecting approximately 50 million people globally, including up to 4 million in the US.
Atea Pharmaceuticals (NASDAQ: AVIR) has announced a virtual hepatitis C virus (HCV) key opinion leader (KOL) panel discussion scheduled for May 14, 2025, at 10:00 AM ET. The event will feature prominent physicians and experts from the US and internationally, specializing in hepatology, gastroenterology, and infectious diseases.
The panel will discuss current HCV patient challenges, results from Atea's Phase 2 study of bemnifosbuvir (nucleotide analog polymerase inhibitor) and ruzasvir (NS5A inhibitor) combination therapy, and potential benefits of a new optimized HCV treatment. Company management will also present the HCV commercial market opportunity and ongoing global Phase 3 clinical development.
Additionally, Atea will release its Q1 2025 financial results on May 12, 2025, after market close, but will not host a quarterly earnings call until Q2 2025 results.
Atea Pharmaceuticals (Nasdaq: AVIR) has announced that full results from their Phase 2 clinical study of bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment will be presented at the EASL Congress 2025 in Amsterdam. The study met its primary endpoints for efficacy and safety.
The abstract TOP-251 was selected as a top poster, highlighting the regimen's potential best-in-class profile, featuring short treatment duration, low drug-drug interaction risk, and no food effect requirements. The presentation will take place May 7-10, 2025.
Additional presentations will cover pharmacokinetics and safety results, including studies on hepatic impairment, renal impairment, and drug interactions. HCV remains a significant global health challenge, with approximately 50 million people chronically infected worldwide and 1 million new infections annually. In the US alone, 2.4-4 million people are estimated to have HCV.
Atea will host a virtual KOL investor event on May 14, 2025, featuring HCV experts discussing the Phase 2 results and market opportunities.
Atea Pharmaceuticals (NASDAQ: AVIR) has announced significant corporate changes, including the appointment of Howard H. Berman, Ph.D. to its Board of Directors and a $25 million share repurchase program. Dr. Berman will initially serve as a non-voting observer until Atea's 2025 Annual Meeting, when he will become a full voting member.
The appointment comes as part of an agreement with the Radoff-JEC Group, who has withdrawn their slate of director candidates and agreed to vote in favor of Atea's Board nominees. Additionally, Franklin Berger will not seek reelection at the 2027 Annual Meeting.
The company is currently advancing a global Phase 3 program evaluating bemnifosbuvir and ruzasvir for hepatitis C virus (HCV) treatment. As previously announced in December 2024, Atea has engaged Evercore to explore strategic alternatives, including potential partnerships, mergers, acquisitions, or asset sales.
Atea Pharmaceuticals (NASDAQ: AVIR) has initiated its Phase 3 trial C-BEYOND, dosing the first patient to evaluate the combination of bemnifosbuvir and ruzasvir for treating chronic hepatitis C virus (HCV). The open-label trial, conducted in the US and Canada, compares this regimen to sofosbuvir and velpatasvir.
The bemnifosbuvir-ruzasvir regimen will be administered once-daily for 8 weeks in patients without cirrhosis and 12 weeks in patients with compensated cirrhosis. The trial's control arm will receive a 12-week treatment.
The company aims to address the significant global HCV burden, affecting approximately 50 million people worldwide, with 1 million new infections annually. In the US alone, 2.4-4 million people are estimated to have HCV, with new infections exceeding treatment rates. The new regimen offers potential advantages including shorter treatment duration, low drug-drug interaction risk, and no food effect requirements.
FAQ
What is the current stock price of Atea Pharmaceuticals (AVIR)?
What is the market cap of Atea Pharmaceuticals (AVIR)?
